Epanova® for Lowering Very High Triglycerides

Severe Hypertriglyceridemia Clinical Trial

— EVOLVE  

Official title:

Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01242527
• Other study ID #: OM-EPA-003
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: November 15, 2010
• Last updated: June 27, 2013
• Start date: January 2011
• Est. completion date: April 2012

Study information

• Verified date: June 2013
• Source: Omthera Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationHungary: National Institute of PharmacyDenmark: Ethics CommitteeNetherlands: Medical Ethics Review Committee (METC)Russia: Ministry of Health of the Russian FederationIndia: Drugs Controller General of India
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 399
• Est. completion date: April 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men or women, >=18 years of age.

• Very high serum TG values in the range >=500 mg/dL and <2000 mg/dL (>=5.65 mmol/L and <22.60 mmol/L)

Exclusion Criteria:

• Allergy or intolerance to omega-3 fatty acids, omega-3-acid ethyl esters, or fish.

• Known lipoprotein lipase impairment or deficiency or apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.

• Unable to discontinue use of omega-3 drugs/supplements.

• Unable to discontinue use of bile acid sequestrants, fibrates or niacin (other than niacin-containing vitamins <200 mg), or any supplement used to alter lipid metabolism.

• Women who are pregnant, lactating, or planning to become pregnant. Women of childbearing potential who are not using acceptable contraceptive methods.

• Use of tamoxifen, estrogens or progestins that has not been stable for >4 weeks prior to Visit 1.

• Use of oral or injected corticosteroids or anabolic steroids.

• History of pancreatitis.

• History of symptomatic gallstone disease, unless treated with cholecystectomy.

• Uncontrolled diabetes.

• Uncontrolled hypothyroidism or thyroid stimulating hormone (TSH).

• History of cancer (other than basal cell carcinoma) in the past 2 years.

• Cardiovascular event (i.e., myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient ischemic attack, unstable congestive heart failure requiring a change in treatment) or revascularization procedure within six months prior to Visit 1.

• Use of anticoagulants (e.g. warfarin [Coumadin®], coumarin, heparin, enoxaparin, clopidogrel).

• Presence of an aortic aneurysm or resection of an aortic aneurysm within six months prior to Visit 1.

• Recent history (within six months prior to Visit 1) or current significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal or immunologic disease.

• Poorly controlled hypertension.

• Any of the following laboratory criteria: serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST), glucose, glomerular filtration rate (GFR), platelet count,or hemoglobin outside of study range.

• Recent history (past 12 months) of drug abuse or alcohol abuse.

• Exposure to any investigational product, within 4 weeks prior to Visit 1.

• Presence of any other condition the Investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertriglyceridemia
• Severe Hypertriglyceridemia

Intervention

Drug:
• placebo
4 capsules (1g) daily for 12 weeks
• omefas
2 capsules (1g) + 2 placebo daily for 12 weeks
• omefas
3 capsules (1g) + 1 placebo daily for 12 weeks
• omefas
4 capsules (1g)daily for 12 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Omthera Pharmaceuticals, Inc

Countries where clinical trial is conducted

United States,  Denmark,  Hungary,  India,  Netherlands,  Russian Federation,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fasting Serum Triglycerides	The primary endpoints are the differences in mean percent changes from baseline to end-of-treatment in triglycerides between placebo and the 2g/day, 3g/day and 4g/day Epanova groups.	12 weeks	No